.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for addition of people with MASLD and also dimension of liver end results in cardio-- renal-- metabolic tests, when data recommend mechanistically plausible perks as well as clinical safety and security-- as well as describes factors for trial style and regulative commendation.